Angiogenesis
Angiogenesis is the growth of new blood vessels from the existing vasculature. This process is involved in development, wound healing, embryo formation and tumor growth. Activation of angiogenesis leads to the release of pro-angiogenic growth factors such as VEGF, PDGF, FGF and TGF, which bind their receptors on endothelial cells within pre-existing vessels. As a result, it induces signal transduction of various pathways such as PI3K/Akt, Erk1/2, Smad and Notch, causing endothelial cells proliferation and migration. Endothelial cells use matrix metalloproteases and integrins to digest extracellular matrix and migrate into new area, where they lengthen and form tubes, generating new blood vessel.
During tumor angiogenesis, cancer cells stimulate formation of new blood vessel for delivering oxygen and nutrients to a tumor. As the tumor grows, cells at the center of the mass become starved of oxygen, causing hypoxia. It stabilizes the expression of a transcription factor, HIF-1α (hypoxia inducible factor-1), which binds HIF-1β to upregulate the expression of several angiogenesis-promoting genes. Moreover, growth factor signaling also stimulates HIF-1 activity in order to maintain oxygen homeostasis for growing cells.
- B5699 P11Summary: 整合素αvβ3-玻连蛋白相互作用的拮抗剂
- B5675 ObtustatinSummary: 整合素α1β1抑制剂
- B5644 LDV FITCSummary: 结合α4β1整联蛋白(VLA-4)的荧光配体
- B5391 Echistatin, α1 isoformSummary: αVβ3整联蛋白拮抗剂
- B7412 RGDS peptideSummary: 抑制整联蛋白受体功能的整联蛋白结合序列
- B3708 RGD (Arg-Gly-Asp) Peptides1 CitationTarget: Integrin-ligand interactionsSummary: 抑制整合素结合到RGD基序
- B1115 BAY 87-2243Target: Hypoxia Inducible Factors (HIFs)Summary: 有效的HIF-1选择性抑制剂
- B2298 Plinabulin (NPI-2358)中文名: 普那布林Target: Vascular Disrupting Agents (VDA)Summary: 血管破坏剂
- B3242 PCI-32765 RacemateSummary: BTK抑制剂
- A8677 SLIGKV-NH2中文名: 蛋白酶活化的受体-2,酰胺Summary: PAR2激动剂